
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibit... NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. Show more
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.9 | 3.94736842105 | 22.8 | 24.23 | 22.21 | 1609269 | 23.3771095 | CS |
4 | 4.46 | 23.1808731809 | 19.24 | 24.23 | 17.18 | 1118214 | 21.41324945 | CS |
12 | -1.66 | -6.54574132492 | 25.36 | 26.8 | 17.18 | 794987 | 22.44604431 | CS |
26 | 7.64 | 47.5716064757 | 16.06 | 27.29 | 15.19 | 733103 | 22.42020971 | CS |
52 | 0.27 | 1.152368758 | 23.43 | 27.29 | 15.19 | 489328 | 21.38347026 | CS |
156 | 12.7 | 115.454545455 | 11 | 32.88 | 5.6326 | 272747 | 19.78143235 | CS |
260 | 12.7 | 115.454545455 | 11 | 32.88 | 5.6326 | 272747 | 19.78143235 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales